---
title: "How a Shanghai surgical robot earned EU clearance and ran cross-border remote surgery in Europe"
date: 2026-11-12
category: Humanoids & Robotics
site: NeuroAI
canonical: https://neuroai.site/a/na-robot-toumai-europe-ce
language: en
---

# How a Shanghai surgical robot earned EU clearance and ran cross-border remote surgery in Europe

> MicroPort MedBot's Toumai system secured EU CE certification for its fluorescence imaging and completed the first intra-European remote surgeries.

A surgeon in one Belgian hospital leaned over a console. On a screen, a colleague roughly 56 kilometers away watched the same operating field in 3D. Neither left the building, yet the procedure moved between them in real time.

For years, "remote surgery" meant a lab demo or a single dramatic cross-continent stunt. What changed this year is quieter and more practical: a Chinese-made robot started clearing the regulatory bars that let it work inside Europe's health systems — and then actually did the work.

## Key takeaways

- MicroPort MedBot's Toumai (图迈) multi-port laparoscopic surgical robot received EU CE certification under the Medical Device Regulation (MDR) for its DFVision (蜻蜓眼) 3D fluorescence imaging system in November 2025.

- In May 2025 the CE-certified system completed what the company describes as the first intra-European remote surgeries, linking a site in Melle with a hospital in Aalst, Belgium, at about 20 milliseconds of latency.

- The platform has reached market access in more than 60 countries and regions and has supported over 15,000 procedures worldwide, including nearly 700 remote surgeries across 20-plus countries, per company disclosures.

- Toumai is the only surgical robot platform the company says supports 5G, high/low-orbit satellites, and broadband for remote operations — a claim about reach, not about the operating room itself.

## From a fluorescence camera to a market door

The November 2025 milestone was not the robot arm. It was the eye. DFVision (蜻蜓眼), a 3D fluorescence endoscope, received CE certification under the EU's MDR framework. In cancer surgery, telling tumor edges from healthy tissue is the difference between a clean resection and a recurrence risk. The system uses indocyanine green (ICG) as a contrast agent and can switch among eight fluorescence display modes in real time, so a surgeon sees both anatomical structure and blood-flow or tumor-margin function inside one fused image.

Why that matters for market access: a surgical robot is only as sellable as its cleared components. A CE mark on the core imaging system lets the whole Toumai ecosystem pitch itself to European hospitals on recognized terms, instead of as an unproven import. It is the kind of regulatory plumbing that turns a product into a purchasable line item.

## The cross-border remote surgeries

Note that these May 2025 remote surgeries inside Belgium took place before the November 2025 CE mark; the CE clearance came afterward.

On 26 May 2025, the company reported two remote procedures inside Belgium. A radical prostatectomy was performed by Dr. Geert De Naeyer operating remotely from Orsi Academy in Melle, with Prof. Alex Mottrie assisting on-site at AZORG Hospital in Aalst. A hysterectomy was led by Dr. Emily Jamaer — described by the company as the first remote surgery by a female surgeon in Europe. The link ran over the hospital's standard network with about 20 ms round-trip latency.

Twenty milliseconds is the interesting number. Human reaction time is an order of magnitude slower, so at that delay a surgeon's hand movements arrive at the robot with no perceptible lag. The company framed the cases as proof that remote robotic surgery can run on ordinary hospital infrastructure, not a bespoke fiber line. Surgeons reported stable, accurate arm movement and fluent real-time voice coordination between the two teams.

## The bigger footprint

The Belgium cases are one data point in a wider map. According to MicroPort MedBot, Toumai has secured market access in more than 60 countries and regions, reached commercial use in over 40, and supported more than 15,000 multi-specialty procedures. Of those, nearly 700 were remote surgeries spanning 20-plus countries, and the company claims over 60 "world-first" clinical milestones.

The system is also unusual in how it connects. The company states Toumai is the only surgical robotic platform compatible with 5G, low-Earth-orbit and geostationary satellites, and broadband networks — the plumbing that lets a specialist in one country operate on a patient in another without a dedicated link. That is a reach claim, not a clinical one, but it explains why remote surgery is the feature investors and hospitals keep returning to. In October 2025, the same platform was used for what was described as the first remote surgery inside the United States, performed under the FDA's Investigational Device Exemption framework between two Florida hospitals — a sign the company is pressing the same capability into the world's largest robotics market.

MicroPort MedBot (上海微创医疗机器人集团) is listed in Hong Kong under code 02252.HK and is a subsidiary of MicroPort Scientific Corporation (微创医疗, 00853.HK). It began laparoscopic robot R&D in 2014 and was formally established in Shanghai in 2015.

## Why a Chinese entrant matters

The surgical-robot market has long been dominated by a single incumbent whose systems cost roughly RMB 20 million (≈ US$2.8M / HK$21.8M) per unit. Industry estimates put Toumai's pricing closer to RMB 13 million (≈ US$1.8M / HK$14.2M) by the company's account, a gap that matters in cost-sensitive public health systems; the comparison is the company's own positioning and the two systems are not strictly identical classes. A cheaper, CE-cleared Chinese platform does not win on brand familiarity, but it changes the procurement math for hospitals that could never justify the incumbent's price.

## What "remote" really changes

Remote surgery is not about a robot thinking for itself. It is about moving a surgeon's hands across a distance that used to require the surgeon to physically travel. In countries with few specialist urologists or gynecologic oncologists, that can mean a patient gets a procedure locally instead of being referred hundreds of kilometers away.

According to Li An, chief scientist at BrainNet (脑机网), remote surgery is less about replacing the surgeon and more about pooling scarce specialist skill across geography — the real bottleneck is training and trust, not the hardware. Li An's comments reflect his own views and do not represent NeuroAI's editorial position or an endorsement by BrainNet (脑机网).

## Honest limitations

This article relies on company disclosures and company-organized clinical demonstrations; MicroPort MedBot sponsored and reported the Belgium cases, so independent verification of surgical outcomes is limited. Cumulative counts (15,000 procedures, 700 remote surgeries, 60+ countries) are company-reported and not independently audited here. The "world's only" satellite-connectivity claim is the company's own positioning and was not benchmarked against competitors in this piece. The US remote-surgery reference is drawn from secondary media reporting of a company-announced procedure. We did not assess per-country regulatory status beyond the EU CE mark, and clinical adoption in any single market may differ from the global totals cited.

## What readers can do now

- If you follow medtech investing, track MicroPort MedBot's (02252.HK) overseas revenue line and per-region installation counts rather than headline procedure totals.

- If you work in hospital procurement, ask vendors for the specific CE/MDR or FDA clearance covering the exact module you plan to buy — a cleared imaging system does not equal a cleared robot.

- If you are a clinician or patient, treat "remote surgery" as a logistics and training question first: who operates the console, and what is the latency and backup plan if the link drops.

---

Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-robot-toumai-europe-ce
Free to quote with attribution and a link to the original.
